Download PDF
Fortschr Neurol Psychiatr 2020; 88(06): 387-397
DOI: 10.1055/a-0918-6071
Übersicht

Frühintervention bei Schizophrenie – ein Update

Early Intervention in Schizophrenia – an Update
Karolina Leopold
1   Vivantes Klinikum am Urban, Psychiatrie, Psychotherapie und Psychosomatik
,
Thomas Becker
2   Universität Ulm, Klinik für Psychiatrie und Psychotherapie II
,
Johann Förstl
3   Klinikum rechts der Isar der Technischen Universitat Munchen, Klinik und Pliklinik für Psychiatrie
,
Falk Kiefer
4   Zentralinstitut fur Seelische Gesundheit, Klinik für Abhängiges VErhalten und Suchtmedizin
,
Walter de Millas
5   Vivantes-Wenckebach-Klinikum, Klinik für Psychiatrie, Psychotherapie und Psychosomatik
,
Wolfgang Janetzky
6   Lundbeck GmbH, Scientific Unit
,
Martin Lambert
7   Universitatsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Psychiatrie und Psychotherapie
,
Andrea Pfennig
8   Universitätsklinikum Dresden, Klinik und Poliklinik für Psychiatrie
,
Andreas Bechdolf
9   Vivantes Klinikum Am Urban, Klinik für Psychiatrie, Psychotherapie und Psychosomatik; University of Melbourne, ORYGEN, The National Centre of Excellence, in Youth Mental Health
› Author Affiliations
› Further Information
    Permissions and Reprints

Corrected by:

Frühintervention bei Schizophrenie – ein UpdateFortschr Neurol Psychiatr 2020; 88(06): e1
DOI: 10.1055/a-1207-6106

Zusammenfassung

In Deutschland werden Psychosen immer noch zu spät diagnostiziert. Die Dauer der unbehandelten Psychose (DUP) liegt im Durchschnitt bei einem Jahr. Daher sollte die Frühintervention einen höheren Stellenwert erhalten. Denn je kürzer die Dauer der DUP, desto höher ist die Wahrscheinlichkeit der dauerhaften Recovery sowie einer besseren Langzeitprognose. Aufklärungsarbeit in der Öffentlichkeit und spezialisierte Früherkennungszentren mit niedrigschwelligem Zugang können die Versorgung und damit die Perspektive der meist jungen Patientinnen und Patienten bereits in der Frühphase der Erkrankung verbessern. Notwendig sind dazu neben der antipsychotischen Therapie evidenzbasierte psychotherapeutische Verfahren, Angehörigen- und Peerarbeit sowie begleitende Angebote, durch die Patientinnen und Patienten individuell darin unterstützt werden, wieder im Arbeitsmarkt integriert zu werden oder zu verbleiben („Individual Placement and Support“, IPS). Während die Möglichkeit zur Frühintervention in einigen Ländern, z. B. Dänemark und Australien, bereits einen Teil der Regelversorgung darstellt, ist Deutschland noch nicht über Modellprojekte hinausgekommen. Dies zu ändern muss eines der wesentlichen Ziele der nächsten Jahre sein. Mit dieser Übersichtsarbeit möchten die Autoren daher zum Weiterdenken und Handeln anregen.

Abstract

In Germany, psychoses are still diagnosed too late. The average duration of untreated psychosis is (DUP) one year. Early intervention should, therefore, be given higher priority. The shorter the duration of the DUP, the higher the probability of permanent recovery and a better long-term prognosis. Public education work and specialised early detection centres with low-threshold access can improve care and thus the prospects of patients, mostly young, and already in the early phase of the disease. In addition to anti-psychotic therapy, evidence-based psychotherapeutic procedures, family and peer work, as well as accompanying offers are necessary to support patients individually in being or remaining reintegrated into the labour market ("Individual Placement and Support", IPS). While in some countries, such as Denmark and Australia, the possibility of early intervention is already part of standard care, Germany has not yet gone beyond model projects. Changing this must be one of the main objectives for the coming years. With this review, the authors would therefore like to encourage further thinking and action.

Schlüsselwörter

Schizophrenie - Frühintervention - Langzeitprognose - DUP

Key words

Schizophrenia - Early Intervention - Long-term Prognosis - DUP


Publication History

Received: 22 November 2018

Accepted: 25 April 2019

Article published online:
18 June 2020

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • Literatur

  • 1 Insel TR. Rethinking schizophrenia. Nature 2010; 468: 187-193.
    CrossrefPubMedGoogle Scholar
  • 2 Leopold K, Zarafonitis-Müller S, Burkhard E. et al. Frühdiagnostik und -behandlung der Schizophrenie. Psychopharmakotherapie 2016; 23: 41-49.
    PubMedGoogle Scholar
  • 3 Klosterkötter J. Prädiktion von Psychosen. Nervenarzt 2014; 85: 1238-1248.
    CrossrefPubMedGoogle Scholar
  • 4 Miller TJ, McGlashan TH, Rosen JL. et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: Predictive validity, interrater reliability, and training to reliability. Schizophr Bull 2003; 29: 703-715.
    CrossrefPubMedGoogle Scholar
  • 5 Yung AR, McGorry PD. The initial prodrome in psychosis: Descriptive and qualitative aspects. Aust N Z J Psychiatry 1996; 30: 587-599.
    CrossrefPubMedGoogle Scholar
  • 6 Lieberman JA, Perkins D, Belger A. et al. The early stages of schizophrenia: Speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 2001; 50: 884-897.
    CrossrefPubMedGoogle Scholar
  • 7 Reddy LF, Llerena K, Kern RS. Predictors of employment in schizophrenia: The importance of intrinsic and extrinsic motivation. Schizophr Res 2016; 176: 462-466.
    CrossrefPubMedGoogle Scholar
  • 8 Nordentoft M, Jeppesen P, Abel M. et al. OPUS study: Suicidal behaviour, suicidal ideation and hopelessness among patients with first-episode psychosis. One-year follow-up of a randomised controlled trial. Br J Psychiatry Suppl 2002; 43: s98-106.
    PubMedGoogle Scholar
  • 9 Hambrecht M, Klosterkötter J, Häfner H. Früherkennung und Frühintervention schizophrener Störungen. Dtsch Arztebl 2002; 99: A 2936-2940.
    PubMedGoogle Scholar
  • 10 Schultze-Lutter F, Michel C, Schmidt SJ. et al. EPA guidance on the early of clinical high risk states of psychoses. Eur Psychiatry 2015; 30: 405-416.
    PubMedGoogle Scholar
  • 11 Addington J, Barbato M. The role of cognitive functioning in the outcome of those at clinical high risk for developing psychosis. Epidemiol Psychiatr Sci 2012; 21: 335-342.
    CrossrefPubMedGoogle Scholar
  • 12 Lin A, Wood SJ, Nelson B. et al. Outcomes of nontransitioned cases in a sample at ultra-high risk for psychosis. Am J Psychiatry 2015; 172: 249-258.
    CrossrefPubMedGoogle Scholar
  • 13 Bechdolf A, Laier S, Kallenbach M. et al. Sollen bei Prodromalstadien der Schizophrenie Antipsychotika zur Psychoseprävention eingesetzt werden? Kontra. Nervenarzt 2015; 86: 1424-1426.
    CrossrefPubMedGoogle Scholar
  • 14 Norman RM, Malla AK. Duration of untreated psychosis: A critical examination of the concept and its importance. Psychol Med 2001; 31: 381-400.
    CrossrefPubMedGoogle Scholar
  • 15 Harris MG, Henry LP, Harrigan SM. et al. The relationship between duration of untreated psychosis and outcome: An eight-year prospective study. Schizophr Res 2005; 79: 85-93.
    CrossrefPubMedGoogle Scholar
  • 16 Schimmelmann BG, Huber CG, Lambert M. et al. Impact of duration of untreated psychosis on pre-treatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohort. J Psychiatr Res 2008; 42: 982-990.
    CrossrefPubMedGoogle Scholar
  • 17 Harrison G, Hopper K, Craig T. et al. Recovery from psychotic illness: A 15- and 25-year international follow-up study. Br J Psychiatr 2001; 178: 506-517.
    CrossrefPubMedGoogle Scholar
  • 18 Bird V, Premkumar P, Kendall T. et al. Early intervention services, cognitive-behavioural therapy and family intervention in early psychosis: Systematic review. Br J Psychiatr 2010; 197: 350-356.
    CrossrefPubMedGoogle Scholar
  • 19 Marin O. Developmental timing and critical windows for the treatment of psychiatric disorders. Nat Med 2016; 22: 1229-1238.
    CrossrefPubMedGoogle Scholar
  • 20 Correll CU, Galling B, Pawar A. et al. Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis: A Systematic Review, Meta-analysis, and Meta-regression. JAMA Psychiatry 2018; 75: 555-565.
    CrossrefPubMedGoogle Scholar
  • 21 Cechnicki A, Cichocki L, Kalisz A. et al. Duration of untreated psychosis (DUP) and the course of schizophrenia in a 20-year follow-up study. Psychiatry Res 2014; 219: 420-425.
    CrossrefPubMedGoogle Scholar
  • 22 Amminger GP, Edwards J, Brewer WJ. et al. Duration of untreated psychosis and cognitive deterioration in first-episode schizophrenia. Schizophr Res 2002; 54: 223-230.
    CrossrefPubMedGoogle Scholar
  • 23 Agid O, Siu CO, Pappadopulos E. et al. Early prediction of clinical and functional outcome in schizophrenia. Eur Neuropsychopharmacol 2013; 23: 842-851.
    CrossrefPubMedGoogle Scholar
  • 24 Barnes TR, Leeson VC, Mutsatsa SH. et al. Duration of untreated psychosis and social function: 1-year follow-up study of first-episode schizophrenia. Br J Psychiatr 2008; 193: 203-209.
    CrossrefPubMedGoogle Scholar
  • 25 Farooq S, Large M, Nielssen O. et al. The relationship between the duration of untreated psychosis and outcome in low-and-middle income countries: A systematic review and meta analysis. Schizophr Res 2009; 109: 15-23.
    CrossrefPubMedGoogle Scholar
  • 26 Perkins DO, Gu H, Boteva K. et al. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: A critical review and meta-analysis. Am J Psychiatry 2005; 162: 1785-1804.
    CrossrefPubMedGoogle Scholar
  • 27 Boonstra N, Klaassen R, Sytema S. et al. Duration of untreated psychosis and negative symptoms–A systematic review and meta-analysis of individual patient data. Schizophr Res 2012; 142: 12-19.
    CrossrefPubMedGoogle Scholar
  • 28 Marshall M, Lewis S, Lockwood A. et al. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: A systematic review. Arch Gen Psychiatr 2005; 62: 975-983.
    CrossrefPubMedGoogle Scholar
  • 29 Haas GL, Garratt LS, Sweeney JA. Delay to first antipsychotic medication in schizophrenia: Impact on symptomatology and clinical course of illness. J Psychiatr Res 1998; 32: 151-159.
    CrossrefPubMedGoogle Scholar
  • 30 Hegelstad WT, Larsen TK, Auestad B. et al. Long-term follow-up of the TIPS early detection in psychosis study: Effects on 10-year outcome. Am J Psychiatry 2012; 169: 374-380.
    CrossrefPubMedGoogle Scholar
  • 31 DGPPN (Hrsg.). S3-Leitlinie Schizophrenie. 2019 AWMF-Register Nr. 038–009. https: / /www.awmf.org/leitlinien/detail/ll/038-009.html; Stand: 25 / 03/2019.
    PubMedGoogle Scholar
  • 32 Lloyd-Evans B, Crosby M, Stockton S. et al. Initiatives to shorten duration of untreated psychosis: Systematic review. Br J Psychiatry 2011; 198: 256-263.
    CrossrefPubMedGoogle Scholar
  • 33 NICE (National Institute for Health and Care Excellence). Psychosis and schizophrenia in adults: Prevention and management Clinical guideline. Published 2014. https: / /www.nice.org.uk/guidance/cg178; Stand: 25 / 03/2019.
    PubMedGoogle Scholar
  • 34 Güttgemanns J, Buch A, Sevecke K. et al. Jugendliche mit psychotischen Störungen: Rationale und Konzept einer kognitiv-verhaltenstherapeutischen Intervention [Early onset psychosis: Rationale and concept of a cognitive-behavioral intervention]. Fortschr Neurol Psychiatr 2011; 79: 524-530.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 35 Kohler CG, Turner TH, Bilker WB. et al. Facial emotion recognition in schizophrenia: Intensity effects and error pattern. Am J Psychiatry 2003; 160: 1768-1774.
    CrossrefPubMedGoogle Scholar
  • 36 Wykes T, Steel C, Everitt B. et al. Cognitive behavior therapy for schizophrenia: Effect sizes, clinical models, and methodological rigor. Schizophr Bull 2008; 34: 523-537.
    PubMedGoogle Scholar
  • 37 Pharoah F, Mari J, Rathbone J. et al. Family intervention for schizophrenia. Cochrane Database Syst Rev 2010; (12) Cd000088. DOI: 10.1002/14651858.CD000088.pub2.
    PubMedGoogle Scholar
  • 38 Sin J, Norman I. Psychoeducational interventions for family members of people with schizophrenia: A mixed-method systematic review. J Clin Psychiatry 2013; 74: e1145-1162.
    CrossrefPubMedGoogle Scholar
  • 39 Bäuml J, Pitschel-Walz GH. Psychoedukation bei schizophrenen Erkrankungen: Konsensuspapier der Arbeitsgruppe „Psychoedukation bei schizophrenen Erkrankungen“. 2. Aufl. Stuttgart: Schattauer; 2007: 2.
    Google Scholar
  • 40 Pitschel-Walz G, Leucht S, Bäuml J. et al. The effect of family interventions on relapse and rehospitalization in schizophrenia–A meta-analysis. Schizophr Bull 2001; 27: 73-92.
    CrossrefPubMedGoogle Scholar
  • 41 Xia J, Merinder LB, Belgamwar MR. Psychoeducation for schizophrenia. Cochrane Database Syst Rev 2011; (06) Cd002831. DOI: 10.1002/14651858.CD002831.pub2.
    PubMedGoogle Scholar
  • 42 Kasper S, Psota G, Fruhwürth G. et al. Depot-Antipsychotika/-Neuroleptika CliniCum neuropsy. 2011; 3: 1-16.
    PubMedGoogle Scholar
  • 43 Linroth R, Zander S, Forde S. et al. Ramsey county day treatment services. Occup Ther Health Care 1996; 10: 89-103.
    PubMedGoogle Scholar
  • 44 Christensen TO. The influence of neurocognitive dysfunctions on work capacity in schizophrenia patients: A systematic review of the literature. Int J Psychiatry Clin Pract 2007; 11: 89-101.
    CrossrefPubMedGoogle Scholar
  • 45 Ruesch P, Meyer PC, Graf J. et al. Beschäftigungslage von Schizophrenie- und Affektkranken [Employment situation of psychiatric in-patients with schizophrenic or affective disorders]. Psychiatr Prax 2002; 29: 68-75.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 46 Killackey E, Jackson HJ, McGorry PD. Vocational intervention in first-episode psychosis: Individual placement and support v. treatment as usual. Br J Psychiatry 2008; 193: 114-120.
    CrossrefPubMedGoogle Scholar
  • 47 Bond GR, Drake RE, Becker DR. An update on randomized controlled trials of evidence-based supported employment. Psychiatr Rehabil J 2008; 31: 280-290.
    CrossrefPubMedGoogle Scholar
  • 48 Mahlke CI, Kramer UM, Becker T. et al. Peer support in mental health services. Curr Opin Psychiatry 2014; 27: 276-281.
    CrossrefPubMedGoogle Scholar
  • 49 Agid O, Schulze L, Arenovich T. et al. Antipsychotic response in first-episode schizophrenia: Efficacy of high doses and switching. Eur Neuropsychopharmacol 2013; 23: 1017-1022.
    CrossrefPubMedGoogle Scholar
  • 50 Karson C, Duffy RA, Eramo A. et al. Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: A systematic review. Neuropsychiatr Dis Treat 2016; 12: 57-67.
    PubMedGoogle Scholar
  • 51 Takeuchi H, Siu C, Remington G. et al. Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. Neuropsychopharmacology. 2018 DOI: 10.1038/s41386-018-0278-3.
    PubMedGoogle Scholar
  • 52 Zipursky RB, Menezes NM, Streiner DL. Risk of symptom recurrence with medication discontinuation in first-episode psychosis: A systematic review. Schizophr Res 2014; 152: 408-414.
    CrossrefPubMedGoogle Scholar
  • 53 Robinson D, Woerner MG, Alvir JM. et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56: 241-247.
    CrossrefPubMedGoogle Scholar
  • 54 Häfner H. Das Rätsel Schizophrenie. München: Verlag C.H. Beck; 2000. .
    Google Scholar
  • 55 Thompson A, Winsper C, Marwaha S. et al. Maintenance antipsychotic treatment versus discontinuation strategies following remission from first episode psychosis: Systematic review. BJPsych Open 2018; 4: 215-225.
    CrossrefPubMedGoogle Scholar
  • 56 Kishi T, Ikuta T, Matsui Y. et al. Effect of discontinuation v. maintenance of antipsychotic medication on relapse rates in patients with remitted / stable first-episode psychosis: A meta-analysis. Psychol Med 2019; 49: 772-779.
    CrossrefPubMedGoogle Scholar
  • 57 Murray RM, Quattrone D, Natesan S. et al. Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics? Br J Psychiatry 2016; 209: 361-365.
    CrossrefPubMed
  • 58 Thomas SP, Nandhra HS, Singh SP. Pharmacologic treatment of first-episode schizophrenia: A review of the literature. Prim Care Companion CNS Disord. 2012 14. . Published online 2012 Jan 5. doi: 10.4088/PCC.11r01198
    PubMedGoogle Scholar
  • 59 Briggs A, Wild D, Lees M. et al. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: Direct utility elicitation. Health Qual Life Outcomes 2008; 6: 105.
    CrossrefPubMedGoogle Scholar
  • 60 Robinson DG, Woerner MG, Napolitano B. et al. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am J Psychiatry 2006; 163: 2096-2102.
    CrossrefPubMedGoogle Scholar
  • 61 Robinson DG, Gallego JA, John M. et al. A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. Schizophr Bull 2015; 41: 1227-1236.
    CrossrefPubMedGoogle Scholar
  • 62 Britvic D, Maric NP, Doknic M. et al. Metabolic issues in psychotic disorders with the focus on first-episode patients: A review. Psychiatr Danub 2013; 25: 410-415.
    PubMedGoogle Scholar
  • 63 Subotnik KL, Casaus LR, Ventura J. et al. Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial. JAMA Psychiatry 2015; 72: 822-829.
    CrossrefPubMedGoogle Scholar
  • 64 Kirschner M, Theodoridou A, Fusar-Poli P. et al. Patients’ and clinicians’ attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis. Ther Adv Psychopharmacol 2013; 3: 89-99.
    CrossrefPubMedGoogle Scholar
  • 65 Heres S, Lambert M, Vauth R. Treatment of early episode in patients with schizophrenia: The role of long acting antipsychotics. Eur Psychiatry 2014; 29 (Suppl 2): 1409-1413.
    CrossrefPubMedGoogle Scholar
  • 66 McGorry P, Bates T, Birchwood M. Designing youth mental health services for the 21st century: Examples from Australia, Ireland and the UK. Br J Psychiatry Suppl 2013; 54: s30-35.
    PubMedGoogle Scholar
  • 67 https: / /www.headspace.org.au; Stand: 7 / 06/2018.
    PubMed
  • 68 https: / /www.headspace.org.au/assets/headspace-overview.pdf; Stand: 7 / 06/2018.
    PubMed
  • 69 Kane JM, Schooler NR, Marcy P. et al. The RAISE early treatment program for first-episode psychosis: Background, rationale, and study design. J Clin Psychiatry 2015; 76: 240-246.
    CrossrefPubMedGoogle Scholar
  • 70 Lambert M, Bock T, Schottle D. et al. Assertive community treatment as part of integrated care versus standard care: A 12-month trial in patients with first- and multiple-episode schizophrenia spectrum disorders treated with quetiapine immediate release (ACCESS trial). J Clin Psychiatry 2010; 71: 1313-1323.
    CrossrefPubMedGoogle Scholar
  • 71 Nordentoft M, Rasmussen JO, Melau M. et al. How successful are first episode programs? A review of the evidence for specialized assertive early intervention. Curr Opin Psychiatry 2014; 27: 167-172.
    CrossrefPubMedGoogle Scholar
  • 72 Konnopka A, Klingberg S, Wittorf A. et al. Die Kosten der Schizophrenie in Deutschland: Ein systematischer Literaturuberblick. [The cost of schizophrenia in Germany: A systematic review of the literature]. Psychiatr Prax 2009; 36: 211-218.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 73 Püschner F. Analyse der regionalen psychiatrischen Versorgung im Rhein-Kreis Neuss aus Patienten- und Versorgerperspektive. Gesundheitsökonomie: Politik und Management. Berlin: LIT Verlag Dr. W. Hopf; 2012. .
    Google Scholar
  • 74 Hastrup LH, Kronborg C, Bertelsen M. et al. Cost-effectiveness of early intervention in first-episode psychosis: Economic evaluation of a randomised controlled trial (the OPUS study). Br J Psychiatry 2013; 202: 35-41.
    CrossrefPubMedGoogle Scholar
  • 75 Lang FU, Guhne U, Riedel-Heller SG. et al. Innovative patientenzentrierte Versorgungssysteme: Internationale Perspektiven. [Innovative patient-centered care systems: International perspectives]. Nervenarzt 2015; 86: 1313-1319.
    CrossrefPubMedGoogle Scholar
  • 76 Angermeyer MC, Matschinger H, Carta MG. et al. Changes in the perception of mental illness stigma in Germany over the last two decades. Eur Psychiatry 2014; 29: 390-395.
    CrossrefPubMedGoogle Scholar
  • 77 Gulliver A, Griffiths KM, Christensen H. Perceived barriers and facilitators to mental health help-seeking in young people: A systematic review. BMC Psychiatry 2010; 10: 113.
    CrossrefPubMedGoogle Scholar
  • 78 http: / /www.verrueckt-na-und.de; Stand: 7 / 06/2018.
    PubMed
  • 79 Bundesgesetzblatt Jahrgang 2015 Teil I Nr. 30, ausgegeben zu Bonn am 22. Juli 2015.
    PubMedGoogle Scholar
  • 80 Bundesgesetzblatt Jahrgang 2015 Teil I Nr. 31, ausgegeben zu Bonn am 24. Juli 2015.
    PubMedGoogle Scholar
  • 81 Statistisches Bundesamt. Fachserie 12, Reihe 6.2.1, 2016 Krankenhausstatistik – Diagnosedaten der Patientinnen und Patienten in Krankenhäusern. , 2016
    PubMedGoogle Scholar
  • 82 Jaaskelainen E, Juola P, Hirvonen N. et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull 2013; 39: 1296-1306.
    CrossrefPubMedGoogle Scholar
  • 83 McGorry PD, Yung AR. Early intervention in psychosis: An overdue reform. Aust N Z J Psychiatry 2003; 37: 393-398.
    CrossrefPubMedGoogle Scholar
  • 84 Früherkennungs- und Therapiezentrum für psychische Krisen (FETZ). www.fetz.org/html/links.html; Stand: 19 / 03/2018.
    PubMed
  • 85 Fegert JM, Hauth I, Banaschewski T. et al. Übergang zwischen Jugend- und Erwachsenenalter: Herausforderungen für die Transitionspsychiatrie. Eckpunktepapier von DGKJP und DGPPN. Z Kinder Jugendpsychiatr Psychother 2017; 45: 80-85.
    CrossrefPubMedGoogle Scholar